Make the Diagnosis

A White female presented with pustules and erythematous macules on the left palm

A 53-year-old White female presented with itchy pustules and erythematous macules on the left palm. She has a 20 plus-year history of similar lesions on the palms and soles that come and go, and a history of uveitis. Her sister has a history of Crohn's disease.

What's your diagnosis?

Dyshidrotic eczema

Bullous tinea

Contact dermatitis

Palmoplantar psoriasis

Sneddon-Wilkinson disease

Psoriasis is an immune-mediated chronic inflammatory disease characterized by well-demarcated, scaly, erythematous plaques. Those who present with the condition often have a family history, which supports recent research uncovering various genes implicated in its pathogenesis. The disease is also associated with other systemic complications, most notably cardiovascular disease.

Palmoplantar psoriasis is a unique manifestation of psoriasis appearing in an acral distribution, but can coexist with plaque psoriasis, which is commonly found on extensor surfaces. This condition is found in a small percentage of patients with psoriasis and presentation varies from hyperkeratotic plaques to pustular lesions. The pustular form is known as palmoplantar pustulosis and is within the spectrum of palmoplantar psoriasis.

Psoriasis is typically a clinical diagnosis and its severity can be measured using the Psoriasis Area and Severity Index. If biopsy is performed, the histology demonstrates parakeratosis, orthokeratosis, loss of the stratum granulosum, and dilated vasculature with an inflammatory cell infiltrate. The keratinocytes present with abnormal differentiation and hyperplasia, and the presence of foci of neutrophils known as “Munro’s microabscesses” in the stratum corneum serve as the hallmark of histological diagnosis. However, it is important to note that appearance can vary based on the stage of the lesion and the subtype of psoriasis present.

Palmoplantar psoriasis can be especially limiting and difficult to treat because of its distribution. Topical steroids, topical vitamin D analogues, and narrow band ultraviolet light therapy can be effective for less severe cases. Methotrexate, biologic treatments, and apremilast can be used for more extensive disease.

Dr. Donna Bilu Martin, Premier Dermatology, MD, Aventura, Fla.

Dr. Donna Bilu Martin

This patient is HLA-B27 positive and has uveitis. The presence of the HLA-B27 allele has been associated with inflammatory bowel disease, uveitis, psoriatic arthritis, and reactive arthritis. It has also been reported to be associated with pustular psoriasis. She responded well to topical steroids and vitamin D analogues.

This case and photo were submitted by Mr. Shapiro at Nova Southeastern University College of Osteopathic Medicine, Davie, Fla., and Dr. Bilu Martin.

Dr. Bilu Martin is a board-certified dermatologist in private practice at Premier Dermatology, MD, in Aventura, Fla. More diagnostic cases are available at mdedge.com/dermatology. To submit a case for possible publication, send an email to dermnews@mdedge.com.

References

1. Psoriasis: Overview and Diagnosis, in “Evidence-Based Psoriasis. Updates in Clinical Dermatology.” (Cham, Switzerland: Springer International, 2018).

2. Merola JF et al. Dermatol Ther. 2018 May;31(3):e12589.

3. Chung J et al. J Am Acad Dermatol. 2014 Oct;71(4):623-32.

Recommended Reading

FDA approves oral TYK2 inhibitor deucravacitinib for treating psoriasis
MDedge Dermatology
Optimizing Narrowband UVB Phototherapy: Is It More Challenging for Your Older Patients?
MDedge Dermatology
Sustained response at 2 years reported for newly approved oral psoriasis agent
MDedge Dermatology
Artemisia capillaris extract
MDedge Dermatology
Brodalumab suicide risk similar to other biologics, postmarket study finds
MDedge Dermatology
Open Clinical Trials for Psoriasis
MDedge Dermatology
Apremilast alleviates severe psoriasis in some children, data show
MDedge Dermatology
Psoriasis, psoriatic arthritis insurance coverage remains restrictive
MDedge Dermatology
Apremilast may have some cardiometabolic benefits in patients with psoriasis
MDedge Dermatology
Medicare Part D Prescription Claims for Brodalumab: Analysis of Annual Trends for 2017-2019
MDedge Dermatology